|Bid||1.0100 x 2200|
|Ask||1.0400 x 1100|
|Day's Range||0.9193 - 1.0900|
|52 Week Range||0.7700 - 12.6000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
The Redwood City, California-based company said it had a loss of 14 cents per share. The medical device maker posted revenue of $1.8 million in the period. In the final minutes of trading on Wednesday, ...
On Wednesday, Mar. 6, Avinger (NASDAQ: AVGR ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Analysts are predicting Avinger will report a ...
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
On a per-share basis, the Redwood City, California-based company said it had a loss of 56 cents. The medical device maker posted revenue of $2 million in the period. The company's shares closed at 31 cents. ...